Top

Published in:

01-05-2008 | Review

Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

Authors: Vincent Launay-Vacher, Jean-Baptiste Rey, Corinne Isnard-Bagnis, Gilbert Deray, Mikael Daouphars

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2008

Abstract

Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).

Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G; the Insuffisance Rénale et Médicaments Anticancéreux (IRMA) Study Group (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drugs management: The IRMA Study. Cancer (in press)

Meijer S, Mulder NH, Sleijfer DT, de Jong PE, Sluiter WJ, Schraffordt Koops H, van der Hem GK (1982) Nephrotoxicity of cis-diamminedichloride platinum [CDDP] during remission-induction and maintenance chemotherapy of the testicular carcinoma. Cancer Chemother Pharmacol 8:27–30PubMedCrossRef

Brock PR, Koliouska DE, Baratt TM, Yeomans E, Pritchard J (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531–534PubMedCrossRef

Yuhas JM, Culo F (1980) Selective inhibition of the nephrotoxicity of cis-dichlorodiamine platinum by WR 272l without altering its antitumor properties. Cancer Treat Rep 64:57–64PubMed

Borch RF, Pleasants ME (1979) Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat renal model. Proc Natl Acad Sci USA 76:6611–6614PubMedCrossRef

Berry J-P, Pauwells C, Tlouzeau S, Lespinats G (1984) Effect of Selenium in combination with cis-diamminedichloroplatinum [II] in the treatment of murine fibrosarcoma. Cancer Res 44:2864–2868PubMed

Citkovic E, Hayes DM, Golbey RB, Krakoff IH (1991) Cisplatin-nephrotoxicity: diethyldithiocarbomate, WR2721 or just water. J Clin Oncol 9:707–709

Litterst CL, Torres IJ, Guarino AM (1977) Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP[II]. J Clin Hematol Oncol 7:169–178

Safirstein R, Daye M, Miller P, Guttenplan J (1980) Renal disposition and metabolism of liganded platinum: implications to toxicity. Fed Proc 40:651A

10.

Safirstein R, Miller P, Guttenplan JB (1984) Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753–758PubMedCrossRef

11.

Jacobs C, Kalman SM, Tretton M, Weiner MW (1980) Renal handling of cis-diammine dichloroplatinum [II]. Cancer Treat Rep 64:1223–1226PubMed

12.

Levi J, Jacobs C, Kalman S, McTigue M, Weiner MWJ (1980) Mechanism of cis-platinum nephrotoxicity I. Effects on sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213:545–550PubMed

13.

Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J (1987) Cisplatin nephrotoxicity insights into mechanism. Int J Androl 10:325–346PubMed

14.

Safirstein RL, Daye M, Guttenplan JB (1983) Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin. Cancer Lett 18:329–338PubMedCrossRef

15.

Bradley LJN, Yacema KJ, Lippard SJ, Essigmann JM (1993) Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum [II]. Biochemistry 32:982–988PubMedCrossRef

16.

Greene MH (1992) Is cisplatin a human carcinogen? J Natl Cancer Inst 84:306–312PubMedCrossRef

17.

Winston JA, Safirstein R (1985) Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490–F496PubMed

18.

Hutchinson FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen G (1988) Renal salt-wasting in patients treated with cisplatin. Ann Intern Med 108:21–25

19.

Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cis-diamminedichloroplatinum II. Ann Intern Med 90:929–931PubMed

20.

Schilsky RL, Barlock A, Ozols RF (1982) Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep 66:1767–1769PubMed

21.

Mavichak V, Wong NLM, Quamme GA, Magil AB, Sutton RAL, Dirks JH (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28:914–921PubMedCrossRef

22.

Swainson CP, Colls BM, Fitzharris BM (1985) Cisplatinium and distal renal tubule toxicity. N Z Med J 98:375–378PubMed

23.

Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J (1987) Cisplatin nephrotoxicity insights into mechanism. Int J Androl 10:325–346PubMedCrossRef

24.

Schor N, Ichikawa I, Rennke HG, Troy JL, Brenner BM (1981) Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int 19:288–292PubMedCrossRef

25.

Gordon JA, Gattone VH (1986) Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991–F998PubMed

26.

Brady HR, Kone BC, Stroniski ME, Zeidel ML, Giebisch G, Gullans SR (1990) Mitochondrial injury: an early event in cisplatin-toxicity to renal proximal tubules. Am J Physiol 258:F1181–F1187PubMed

27.

Harder HC, Rosenberg B (1970) Inhibitory effects of anti-tumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Int J Cancer 6:207–216PubMedCrossRef

28.

Howle JA, Gale GR (1970) cis-Dichlorodiammine platinum II persistent and selective inhibition of deoxyribonucleic acid synthesis in vitro. Biochem Pharmacol 19:2757–2762PubMedCrossRef

29.

Munchausen LL, Rahn RO (1975) Biological and chemical effects of cis-dichlorodiammineplatinum [II] on DNA. Cancer Chemother Rep 59:643–646PubMed

30.

Roberts JJ, Prascoe JM (1972) Cross linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature 235:282–284PubMedCrossRef

31.

Zwelling LA, Anderson T, Kohn KW (1979) DNA-protein and DNA interstrand cross-linking by cis- and trans platinum [II] Diamminedichloride in Ll2lO mouse leukemia cells and relation to cytotoxicity. Cancer Res 39:365–369PubMed

32.

Fraval HNA, Rawlings CJ, Roberts JJ (1978) Increased sensitivity of UV repair deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus leuteus. Mutat Res 51:12l–32

33.

Yano T, Itoh Y, Matsuo M, Kawashiri T, Egashira N, Oishi R (2007) Involvement of both tumor necrosis factor-alpha-induced necrosis and p53-mediated caspase-dependent apoptosis in nephrotoxicity of cisplatin. Apoptosis 12:1901–1909PubMedCrossRef

34.

Shino Y, Itoh Y, Kubota T, Yano T, Sendo T, Oishi R (2003) Role of poly(ADP-ribose)polymerase in cisplatin-induced injury in LLC-PK1 cells. Free Radic Biol Med 35(8):966–977PubMedCrossRef

35.

Safirstein R, Zelent AZ, Gordon R (1988) Cisplatin-nephrotoxicity: new insights into mechanisms. In: Hacker MP, Lazo JS, Tritton TR (eds) Organ directed toxicities of anticancer drugs. Martinus Nijhof, Boston, pp 172–189

36.

Madias NE, Harrington JT (1978) Platinium nephrotoxicity. Am J Med 65:307–314PubMedCrossRef

37.

Goldstein RS, Mayor GH (1983) Minireview: the nephrotoxicity of cisplatin. Life Sci 32:685–690PubMedCrossRef

38.

Heidemann HTH, Gerkens JF, Jackson EK, Branch RA (1985) Attenuation of cisplatin-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn Schmiedebergs Arch Pharmacol 329:201–205PubMedCrossRef

39.

Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IA (1977) High dose cisplatinium diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372–1381PubMedCrossRef

40.

Tark JJ, Howell SB (1978) Nephrotoxicity of cisplatinium [II]-dichlorodiammine. Clin Pharmacol Ther 23:461–466

41.

Einhorn LH, Donohue J (1977) cis Diammine dichloroplatinium, uniblastine and gleomycine combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293PubMed

42.

Cvitkovic B, Spaulding J, Bethune V, Martin J, Whitemore WF (1977) Improvement of cis-dichlorodiammineplatinum therapeutic index in an animal model. Cancer 39:1357–1361PubMedCrossRef

43.

Pera MF Jr, Zook BC, Harder HC (1979) Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammine platinum [II] in rats. Cancer Res 29:1269–1278

44.

Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pretreatment on clinical morphological and ultrastructural cis-platinium induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5:1393–1399PubMed

45.

Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31–35PubMed

46.

Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13–18PubMedCrossRef

47.

Salem P, Khalyl M, Jabboury K, Hashimi L (1984) cis-Diamminedichloroplatinium [II] by a 5-day continuous infusion. Cancer 53:837–840PubMedCrossRef

48.

Haas A, Anderson L, Lad T (1983) The influence of aminoglycosides on the nephrotoxicity of cis-diammine-chloroplatinium in cancer patients. J Infect Dis 147:363PubMed

49.

Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1978) Acute renal failure after cis-dichlorodiammine-platinium [II] and gentamicin-cephalotin therapies. Cancer Treat Rep 62:693

50.

Jongejan HTM, Provost AP, Molenar JC (1988) Potentiation of cis-diamminedichloroplatinium nephrotoxicity by amikacin in rats. Cancer Chemother Pharmacol 22:178–180PubMedCrossRef

51.

Bregman CL, Williams PD (1986) Comparative nephrotoxicity of carboplatin and cisplatin in combination with actinomycin. Cancer Chemother Pharmacol 18(2):117–123PubMedCrossRef

52.

Hirosawa A, Niitani H, Hayashibara K, Tsubo IE (1989) Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammine platinium and vindesine. Cancer Chemother Pharmacol 23:255–258PubMedCrossRef

53.

Howell S, Pfeifle C, Wung W, Olshen R, Lucas W, Yon J, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851PubMed

54.

Levey AS, Greene T, Kusek JW et al (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:0828 abstract

55.

Cockcroft DW, Gault MH (1976) Prediction of CrCl from serum creatinine. Nephron 16:31–41PubMed

56.

National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266

57.

Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100PubMedCrossRef

58.

Hodgkinson E, Neville-Webbe HL, Coleman RE (2006) Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) 18(9):710–718

59.

Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacity of odansetron and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med 322(12):810–815PubMedCrossRef

Title: Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care
Authors: Vincent Launay-Vacher
Jean-Baptiste Rey
Corinne Isnard-Bagnis
Gilbert Deray
Mikael Daouphars
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0711-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2008

Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats

Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth

Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

Keynote webinar | Spotlight on antibody–drug conjugates in cancer